|
DE3681787D1
(de)
|
1985-07-05 |
1991-11-07 |
Whitehead Biomedical Inst |
Expression von fremdem genetischem material in epithelzellen.
|
|
US4980286A
(en)
|
1985-07-05 |
1990-12-25 |
Whitehead Institute For Biomedical Research |
In vivo introduction and expression of foreign genetic material in epithelial cells
|
|
HK1008049A1
(en)
|
1987-09-11 |
1999-04-30 |
Whitehead Institute For Biomedical Research |
Transduced fibroblasts and use therefor
|
|
US5824311A
(en)
|
1987-11-30 |
1998-10-20 |
Trustees Of The University Of Pennsylvania |
Treatment of tumors with monoclonal antibodies against oncogene antigens
|
|
ATE110108T1
(de)
|
1987-12-11 |
1994-09-15 |
Whitehead Biomedical Inst |
Genetische modifizierung von endothelialen zellen.
|
|
DE68927996T2
(de)
|
1988-02-05 |
1997-12-04 |
Hughes Howard Med Inst |
Modifizierte hepatozyten und deren anwendung
|
|
US4870287A
(en)
|
1988-03-03 |
1989-09-26 |
Loma Linda University Medical Center |
Multi-station proton beam therapy system
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
DE69123981T3
(de)
|
1990-10-31 |
2006-06-14 |
Cell Genesys Inc |
Nützliche retrovirale vektoren für die gentherapie
|
|
JPH07503124A
(ja)
|
1991-06-14 |
1995-04-06 |
ゾーマ・コーポレーション |
微生物によって生産される抗体断片とそれらの複合体
|
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
|
SE9201984D0
(sv)
|
1992-06-29 |
1992-06-29 |
Pharmacia Biosensor Ab |
Improvement in optical assays
|
|
US5846945A
(en)
|
1993-02-16 |
1998-12-08 |
Onyx Pharmaceuticals, Inc. |
Cytopathic viruses for therapy and prophylaxis of neoplasia
|
|
US5801005A
(en)
|
1993-03-17 |
1998-09-01 |
University Of Washington |
Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
|
|
US5885573A
(en)
|
1993-06-01 |
1999-03-23 |
Arch Development Corporation |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
|
JPH08506247A
(ja)
|
1993-07-09 |
1996-07-09 |
アムジェン ボールダー インコーポレイテッド |
組換えctla4ポリペプチドおよびその製造方法
|
|
US5308341A
(en)
|
1993-09-28 |
1994-05-03 |
Becton, Dickinson And Company |
Method of testing the dose accuracy of a medication delivery device
|
|
US5443505A
(en)
|
1993-11-15 |
1995-08-22 |
Oculex Pharmaceuticals, Inc. |
Biocompatible ocular implants
|
|
GB9506466D0
(en)
|
1994-08-26 |
1995-05-17 |
Prolifix Ltd |
Cell cycle regulated repressor and dna element
|
|
US5773019A
(en)
|
1995-09-27 |
1998-06-30 |
The University Of Kentucky Research Foundation |
Implantable controlled release device to deliver drugs directly to an internal portion of the body
|
|
US5760395A
(en)
|
1996-04-18 |
1998-06-02 |
Universities Research Assoc., Inc. |
Method and apparatus for laser-controlled proton beam radiology
|
|
US5739169A
(en)
|
1996-05-31 |
1998-04-14 |
Procept, Incorporated |
Aromatic compounds for inhibiting immune response
|
|
US5844905A
(en)
|
1996-07-09 |
1998-12-01 |
International Business Machines Corporation |
Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange
|
|
US6146361A
(en)
|
1996-09-26 |
2000-11-14 |
Becton Dickinson And Company |
Medication delivery pen having a 31 gauge needle
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
EP0970128A1
(en)
|
1997-03-21 |
2000-01-12 |
Brigham And Women's Hospital |
Immunotherapeutic ctla-4 binding peptides
|
|
JP3876002B2
(ja)
|
1997-04-14 |
2007-01-31 |
ミクロメート・アクチエンゲゼルシャフト |
抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
|
|
WO1998047531A2
(en)
|
1997-04-21 |
1998-10-29 |
Arch Development Corporation |
Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
|
|
US6329516B1
(en)
|
1997-04-28 |
2001-12-11 |
Fmc Corporation |
Lepidopteran GABA-gated chloride channels
|
|
US6302855B1
(en)
|
1998-05-20 |
2001-10-16 |
Novo Nordisk A/S |
Medical apparatus for use by a patient for medical self treatment of diabetes
|
|
ES2706547T3
(es)
|
1998-12-23 |
2019-03-29 |
Pfizer |
Anticuerpos monoclonales humanos para CTLA-4
|
|
NZ513356A
(en)
|
1999-02-05 |
2004-01-30 |
Univ Leiden |
Method of modulating metabolite biosynthesis in recombinant cells using an AP2-domain transcription factor that is involved in the response of a plant cell to a jasmonate
|
|
US6192891B1
(en)
|
1999-04-26 |
2001-02-27 |
Becton Dickinson And Company |
Integrated system including medication delivery pen, blood monitoring device, and lancer
|
|
WO2001009300A2
(en)
|
1999-08-02 |
2001-02-08 |
Keygene N.V. |
Method for generating cgmmv resistant plants, genetic constructs, and obtained cgmmv-resistant plants
|
|
US6277099B1
(en)
|
1999-08-06 |
2001-08-21 |
Becton, Dickinson And Company |
Medication delivery pen
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
NZ517202A
(en)
|
1999-08-24 |
2004-05-28 |
Medarex Inc |
Human CTLA-4 antibodies and their uses
|
|
DE19955408A1
(de)
|
1999-11-18 |
2001-05-23 |
Bayer Ag |
GABA-B-Rezeptoren
|
|
PE20011227A1
(es)
|
2000-04-17 |
2002-01-07 |
Chiesi Farma Spa |
Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
|
|
ATE547080T1
(de)
|
2000-08-30 |
2012-03-15 |
Univ Johns Hopkins |
Vorrichtungen zur intraokularen arzneimittelabgabe
|
|
EP1355919B1
(en)
|
2000-12-12 |
2010-11-24 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
|
JP4383168B2
(ja)
|
2001-09-12 |
2009-12-16 |
ベクトン・ディキンソン・アンド・カンパニー |
マイクロ針投与デバイスおよび薬物投与デバイス
|
|
US20050271660A1
(en)
|
2002-09-06 |
2005-12-08 |
Alexion Pharmaceuticals, Inc. |
Nebulization of monoclonal antibodies for treating pulmonary diseases
|
|
US20040102469A1
(en)
|
2002-09-13 |
2004-05-27 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Method for reducing the mortality rate
|
|
GB0222023D0
(en)
|
2002-09-21 |
2002-10-30 |
Aventis Pharma Ltd |
Inhaler
|
|
EP1565482B1
(en)
|
2002-10-23 |
2014-04-30 |
Ludwig Institute for Cancer Research Ltd. |
A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
|
|
FR2849436B1
(fr)
|
2002-12-27 |
2007-01-05 |
Patrick Frayssinet |
Particules et ceramiques de phosphates de calcium pour transfection in vivo et in vitro
|
|
WO2004073551A2
(en)
|
2003-02-18 |
2004-09-02 |
Massachusetts Eye And Ear Infirmary |
Transscleral drug delivery device and related methods
|
|
EP3530736A3
(en)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
|
WO2006130834A2
(en)
|
2005-05-31 |
2006-12-07 |
Board Of Regents, The University Of Texas System |
IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
|
|
PT2170959E
(pt)
|
2007-06-18 |
2014-01-07 |
Merck Sharp & Dohme |
Anticorpos para o receptor humano de morte programada pd-1
|
|
CA2693771A1
(en)
|
2007-07-13 |
2009-01-22 |
Abbott Biotechnology Ltd. |
Methods and compositions for pulmonary administration of a tnf.alpha. inhibitor
|
|
PT2242773T
(pt)
|
2008-02-11 |
2017-09-15 |
Cure Tech Ltd |
Anticorpos monoclonais para o tratamento de tumores
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
WO2010014784A2
(en)
|
2008-08-01 |
2010-02-04 |
Bristol-Myers Squibb Company |
Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
|
|
WO2010098788A2
(en)
|
2008-08-25 |
2010-09-02 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
|
EP2504028A4
(en)
|
2009-11-24 |
2014-04-09 |
Amplimmune Inc |
SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
|
|
EP3053932B1
(en)
|
2010-02-19 |
2020-07-22 |
Xencor, Inc. |
Novel ctla4-ig immunoadhesins
|
|
NZ602220A
(en)
|
2010-03-11 |
2014-10-31 |
Rinat Neuroscience Corp |
Antibodies with ph dependent antigen binding
|
|
JP2014022858A
(ja)
|
2012-07-17 |
2014-02-03 |
Murata Mfg Co Ltd |
電力増幅器
|
|
WO2014087010A1
(en)
|
2012-12-07 |
2014-06-12 |
Ablynx N.V. |
IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
|
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
|
CN105682683A
(zh)
|
2013-08-02 |
2016-06-15 |
阿杜罗生物科技控股有限公司 |
结合cd27激动剂以及免疫检查点抑制以用于免疫刺激
|
|
SMT202300039T1
(it)
|
2013-09-13 |
2023-03-17 |
Beigene Switzerland Gmbh |
Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
|
|
MA45498A
(fr)
*
|
2016-06-16 |
2019-04-24 |
Memorial Sloan Kettering Cancer Center |
Cellules treg génétiquement modifiées
|
|
SG11201900885VA
(en)
*
|
2016-08-01 |
2019-02-27 |
Novartis Ag |
Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
|
|
JP7240335B2
(ja)
*
|
2017-06-20 |
2023-03-15 |
テネオワン, インコーポレイテッド |
抗bcma重鎖のみ抗体
|
|
WO2019099707A1
(en)
*
|
2017-11-16 |
2019-05-23 |
Kite Pharma, Inc |
Modified chimeric antigen receptors and methods of use
|
|
CN113272320A
(zh)
|
2018-11-19 |
2021-08-17 |
得克萨斯大学体系董事会 |
自杀基因
|
|
WO2020227446A1
(en)
|
2019-05-07 |
2020-11-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Enhancement of polypeptides and chimeric antigen receptors via hinge domains
|
|
JP2022548902A
(ja)
|
2019-09-18 |
2022-11-22 |
ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム |
Bcma陽性腫瘍を標的とするためのナチュラルキラー細胞の操作方法
|
|
CN113248611B
(zh)
*
|
2020-02-13 |
2026-02-06 |
上海泰槿生物技术有限公司 |
抗bcma抗体、其药物组合物及应用
|